Flows Coverage: Direxion Daily S&P Biotech Bear 3X ETF (LABD) Rises 7.9% for Nov 22

November 22, 2016 - By Louis Casey   ·   0 Comments

Nov 22 is a positive day so far for Direxion Daily S&P Biotech Bear 3X ETF (NYSEARCA:LABD) as the ETF is active during the day after gaining 7.9% to hit $15.44 per share. The exchange traded fund has 66.71M net assets and 9.79% volatility this month.

Over the course of the day 937,825 shares traded hands, as compared to an average volume of 3.54 million over the last 30 days for Direxion Daily S&P Biotech Bear 3X ETF (NYSEARCA:LABD).

The ETF is -85.89% of its 52-Week High and 3.54% of its low, and is currently having ATR of 2.56. This year’s performance is -52.98% while this quarter’s performance is -31.36%.

The ETF’s YTD performance is -12%, the 1 year is -33.58% and the 3 year is NaN%.

The fund’s top holdings are: S&P Biotechnology Select for 37.11% of assets, Fidelity Institutional Go for 0.00%.

More notable recent Direxion Daily S&P Biotech Bear 3X Shares (NYSEARCA:LABD) news were published by: Marketwatch.com which released: “Direxion Daily S&P Biotech Bear 3X Shares” on March 08, 2014, also Quotes.Wsj.com with their article: “DOW JONES, A NEWS CORP COMPANY” published on May 29, 2015, Etftrends.com published: “Triple-Leveraged Biotech ETFs Could be Coming Soon” on March 20, 2015. More interesting news about Direxion Daily S&P Biotech Bear 3X Shares (NYSEARCA:LABD) were released by: Investorplace.com and their article: “Be Careful Before Loving Leveraged Biotech ETFs” published on October 06, 2015 as well as Marketwatch.com‘s news article titled: “/quotes/zigman/3870025/realtime” with publication date: July 19, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>